|Bid||22.86 x 1100|
|Ask||23.75 x 1100|
|Day's range||23.71 - 24.88|
|52-week range||15.83 - 25.68|
|Beta (5Y monthly)||0.54|
|PE ratio (TTM)||26.02|
|Earnings date||27 July 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.50|
Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel aloneMENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The big shareholder groups in Corcept Therapeutics Incorporated ( NASDAQ:CORT ) have power over the company...